Court rejects Novo bid to block Lilly obesity drug ads

U.S. federal judge Zahid Quraishi denied Novo Nordisk's request for a preliminary injunction to block Eli Lilly's advertising campaign comparing Wegovy and Zepbound. The court found Wegovy prescription volume did not fall while the ads aired, that the ads disclosed the higher-dose Wegovy, and that Novo failed to prove the campaign caused substantial harm to its sales. The ruling addresses only whether to issue an injunction at this stage, and Novo said the underlying dispute over whether the ads are false and misleading remains unresolved.